Lysosome Regulation and Signaling in Aging and Alzheimer's Disease

衰老和阿尔茨海默病中的溶酶体调节和信号传导

• 批准号: 10655043
• 负责人: Hui Zheng
• 金额: $ 25万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-06-01 至 2023-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10655043
• 关键词: Aging; Alzheimer' s Disease; Cell Nucleus; Equipment; Funding; Goals; Immunology; Institutes; Lysosomes; Medical; Medicine; Metabolic; Parents; Pathology; Positioning Attribute; Program Research Project Grants; Regulation; Research; Research Personnel; Signal Pathway; Signal Transduction; System; Tauopathies; base; college; data integration; drug discovery; experimental study; instrument; liquid chromatography mass spectrometry; mass spectrometer; metabolomics; mid-career faculty; professor

This is an equipment supplement application for a Program Project Grant (P01AG066606, June 1, 2021-February 28, 2026, PI: Zheng, Hui). The overarching goal of the parent P01 is to investigate the lysosome-to-nucleus signaling pathways regulating lysosomal homoeostasis in aging and Alzheimer’s disease. The P01 consists of three highly interactive projects and two scientific cores, which are overseen by an administration and data integration core. One of the essential components of the P01 is Core C: Lysosomal Metabolomics and pH. The Core uses high-throughput Mass Spectrometer-based metabolomics to assess changes in lysosomal metabolic activity in aging and tauopathy. The Core C Leader, Meng Wang, is a Professor at Baylor College of Medicine and an Investigator of the Howard Hughes Medical Institute (HHMI). She owns a Thermo Orbitrap Fusion Lumos Tribrid Mass Spectrometer for the lysosomal metabolomics experiments. Recently Dr. Wang has decided to leave Baylor and take on a new position at HHMI Janelia Research Campus, effective August 1, 2022. The Janelia organization is exclusively supported by HHMI and, as a result, Dr. Wang is no longer able to participate in the PPG. In addition, since Dr. Wang purchased mass spec using the HHMI funds, she will need to take the instrument to her new post. We have identified Dr. Feng Li, Associate Professor in the Center for Drug Discovery and the Department of Pathology & Immunology at Baylor College of Medicine and an expert in LC-MS metabolomics, to replace Dr. Wang as the leader for Core C. We have discussed this change and the need for a mass spec with Dr. Paul Barrett, the PO of the P01, who is supportive of the equipment supplement application to purchase a Thermo Scientific™ Orbitrap Exploris 120 LC/MS system to perform lysosome-specific metabolomic profiling as proposed in the parent P01.

这是一份计划项目补助金（P01 AG 066606，6月）的设备补充申请 2021年1月1日至2026年2月28日，主要研究者：Zheng，Hui）。父P01的首要目标是 研究溶酶体到细胞核的信号通路调节溶酶体稳态， 老年痴呆症P01由三个高度互动的项目和两个 科学核心，由行政和数据集成核心监督。之一 P01的基本组成部分是核心C：溶酶体代谢组学和pH。 基于高通量质谱仪的代谢组学评估溶酶体变化 衰老和tau蛋白病的代谢活动。核心C领导人王梦是一位教授， 贝勒医学院和霍华德休斯医学研究所（HHMI）的研究员。 她有一台热轨道阱融合荧光三杂交质谱仪， 代谢组学实验最近王医生决定离开贝勒大学， 职位在HHMI Janelia研究校园，有效的2022年8月1日。Janelia组织 由HHMI独家支持，因此，王博士不再能够参加 PPG。此外，由于王博士使用HHMI基金购买了质谱仪，她将需要 把仪器带到她的新岗位我们已经确定了冯李博士，副教授在 贝勒大学药物发现中心和病理学与免疫学系 医学和LC-MS代谢组学专家，以取代王博士作为核心C的领导者。 我们已经与Paul Barrett博士（PO）讨论了这一变化以及质谱的必要性。 P01，支持设备补充申请购买Thermo Scientific™ Orbitrap Exploris 120 LC/MS系统进行溶酶体特异性代谢组学分析 按照母公司P01中的建议进行分析。